摘要
目的 检测骨肉瘤患者癌组织中人类白细胞分化抗原133(CD133)、细胞增殖核抗原67(Ki67)和核因子-κB(NF-κB)蛋白表达水平,并分析其与临床病理及预后之间的关系。方法 选取本院骨科2015年10月-2020年8月经手术治疗的骨肉瘤患者75例和骨软骨瘤患者52例,分别为骨肉瘤组和骨软骨瘤组。应用免疫组化SP法检测2组患者CD133、Ki67和NF-κB蛋白表达水平,并与临床病理资料和预后相关性进行分析。结果 骨肉瘤组患者CD133、Ki67和NF-κB蛋白阳性率,显著高于骨软骨瘤组,差异有统计学意义(P<0. 05)。CD133、Ki67和NF-κB蛋白表达水平与Enneking分期及有无发生远处转移有关(P<0. 05);与性别、年龄、肿瘤大小、病理类型均无关(P> 0. 05)。骨肉瘤组患者CD133、Ki67和NF-κB蛋白阳性表达者较阴性表达者生存期短,预后差,差异有统计学意义(P<0. 05)。结论 CD133、Ki67和NF-κB蛋白的表达水平高于骨良性肿瘤,有望成为诊断、判定预后标志物。
Objective The levels of human leukocyte differentiation antigen 133(CD133),proliferative nuclear antigen 67(KI67)and nuclear factor-κB(NF-κB)in tumor tissues of patients with osteosarcoma were detected,and their relationship with clinicopathology and prognosis were analyzed.Methods Seventy-five patients with osteosarcoma and 52 patients with osteochondroma were selected from the Department of Orthopaedics of our hospital from October 2015 to August 2020,which were divided into osteosarcoma group and osteochondroma group,respectively.Immunohistochemical SP method was used to detect the levels of CD133,Ki67 and NF-κB in 2 groups,and their correlation with clinicopathological data and prognosis was analyzed.Results The positive rates of CD133,Ki67,and NF-κB protein in tKe osteosarcoma group were significantly higher than the osteochondroma group,and the diHerences were statistically significant(P<0.05).CD133,Ki67 and NF-κB protein levels are related to Enneking staging and the occurrence of distant metastasis(P<0.05);they are not related to gender,age,tumor size,and pathological type,and the differences are not statistically significant(P>0.05).In the osteosarcoma group,patients with positive expression of CD133,Ki67 and NF-κB protein had shorter survival time and poor prognosis than those with negative expression,and the difference was statistically significant(P<0.05).Conclusion The levels of GD133,Ki67 and NF-κB protein are higher than those of benign bone tumors,and they are expected to be diagnostic and prognostic markers.
作者
梁运霞
王潇偲
LIANG Yun-xia;WANG Xiao-si(Shangqiu First People's Hospital,Shangqiu,Henan 476100,China;不详)
出处
《中国卫生检验杂志》
CAS
2021年第21期2641-2644,共4页
Chinese Journal of Health Laboratory Technology
